NDAINJECTIONINJECTABLE
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Fosun Pharma is mechanism of action nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. First approved in 2009.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride is a calcium channel blocker administered via injection that inhibits calcium influx into cardiac and vascular smooth muscle, producing selective vasodilation. It is used to treat hypertension and angina by relaxing coronary and peripheral vascular smooth muscle without significantly impairing cardiac contractility. The injectable formulation enables rapid onset of action in acute care settings.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, indicating potential team downsizing and shift toward generic transition planning.
Mechanism of Action
Mechanism of Action Nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine offers limited career growth potential given its LOE-approaching status and minimal linked job opportunities. This role is best suited for professionals managing mature products or transitioning to pipeline assets.
Brand Manager
Worked on NICARDIPINE HYDROCHLORIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.